Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05169437 · ClinicalTrials.gov registry record · Phase 2
Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
A Phase 2 study, sponsored by Tempus AI.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT05169437 is a Phase 2 study that was terminated before completion, run by Tempus AI. The registered enrollment target is 22 participants.
The verdict
NCT05169437, a Phase 2 study, was terminated before completion, sponsored by Tempus AI.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
Interventions
- DRUG Niraparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-03-15 |
| Est. Completion | 2024-08-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05169437
The ClinicalTrials.gov registry entry for NCT05169437 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tempus AI, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Niraparib is the first listed.
NCT05169437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05169437 about?
NCT05169437 is a clinical study titled "Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors". The purpose of this study is to further evaluate the efficacy and safety of niraparib in patients with locally advanced or metastatic solid tumors and a pathogenic or likely pathogenic tumor PALB2 (tPALB2) mutation.
What is the current status of trial NCT05169437?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2022-03-15. Estimated completion is 2024-08-27.
What interventions are being tested in trial NCT05169437?
The interventions under investigation include: Niraparib (DRUG).
Who is sponsoring clinical trial NCT05169437?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.